| Bioactivity | Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1]. |
| Invitro | Etoposide is capable of causing cytotoxicity on pancreatic β-cells by inducing apoptosis through the JNK/ERK-mediated GSK-3 downstream-triggered mitochondria-dependent signaling pathway in RIN-m5F cells[1].Etoposide and Anti-Human VEGF significantly abolish P1 sphere-forming ability, an effect associated with apoptosis of this subset of cells[2].Etoposide phosphate (0-1μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50s of 0.945 μM; 0.375 μM; and 1.437 μM, respectively[5].Etoposide (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells[5]. Cell Viability Assay[5] Cell Line: |
| Name | Etoposide |
| CAS | 33419-42-0 |
| Formula | C29H32O13 |
| Molar Mass | 588.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |